Intercept slips after dazzling heights; ProNAi rakes in $12M Series C;

@FierceBiotech: Jazz bets up to $397M on Aerial's narcolepsy drug. Story | Follow @FierceBiotech

@JohnCFierce: I predict that today we'll move from deal talk to bold CEO projections at JPMorgan 2014. It is a fun spectator sport. | Follow @JohnCFierce

@DamianFierce: For its next trick, Moderna splits in two with $20M cancer venture. News | Follow @DamianFierce

@EmilyMFierce: Investigators find a way to keep stem cells' options open until they're needed. More | Follow @EmilyMFierce

> Intercept Pharmaceuticals ($ICPT) watched its shares slip earthward after CEO Mark Pruzanski said the biotech may need a Big Pharma partner to get is promising nonalcoholic steatohepatitis treatment onto the market. The company soared more than 500% last week when the drug aced a Phase II treatment but has now come down nearly 40%, trading at around $280 on Tuesday morning. Story

> New York's Microlin Bio is looking to raise as much as $30 million in an IPO to support its early-stage microRNA oncology candidates. S-1

> ProNAi Therapeutics hauled in $12 million in Series C cash to fund the development of PNT2258, a Phase II nucleic acid therapy for lymphoma. News

Medical Device News

@FierceMedDev: JPM 2014: GlySure CEO hits SF to advance the company's ICU glucose monitoring device.  | Follow @FierceMedDev

@MarkHFierce: Phillips is in trouble with the FDA, in part, for conducting a recall and not informing regulators about the details. Warning letter | Follow @MarkHFierce

@MichaelGFierce: Roche's delivery method 'shuttles' Alzheimer's drugs past blood-brain barrier. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Hate getting shots? You might be able to try this painless drug injector soon. Article | Follow @EmilyWFierce

@GalenMoore: Covidien puts Almeida's JPM '14 words into practice with a brace of deals in emerging markets. Report | Follow @GalenMoore

> St. Jude's CEO is still betting on renal denervation, despite Medtronic's setback. Story

> Carlyle Group reportedly nears deal to grab J&J's Ortho Clinical Diagnostics unit. Item

> Qiagen and Exosome pair up for a Dx development deal. News

Pharma News

@FiercePharma: Valeant, Mylan, and Actavis eye Pfizer's brand-new generics unit for buyout: Reuters. Story | Follow @FiercePharma

@TracyStaton: Top story at FiercePharma Monday: Look for an M&A scramble as pharma cash chases higher prices. Story | Follow @TracyStaton

@EricPFierce: India's Aurobindo is looking for more sterile injectable capacity and Actavis has some in the EU for sale. Deal? Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Chinese corruption probe expands as officials detain former Sinopharm exec. More | Follow @CarlyHFierce

> Novartis generic squares off with Glaxo's Advair in third EU country. Item

> AstraZeneca sees earlier patent-cliff recovery, thanks to $4 billion diabetes buyout. Article

> FDA hands pharma marketers another piece of social-media guidance. Story

> Merck CEO: We'll decide fate of animal health, consumer biz by year's end. More

Biotech Research News

> Embryonic-like stem cells created from frozen tissue of Alzheimer's patients. More

> Scientists capture key protein structures that could aid malaria vaccine design. News

> Low doses of cancer drug prevent Type 1 diabetes in mice. Story

> Investigators find a way to keep stem cells' options open until they're needed. Article

> Mimetas, Galapagos partner on organs-on-chip technology. Piece

> European industry-academic partnership seeks miRNA therapies for neurodegenerative diseases. Item

Pharma Manufacturing News

> 11 compounders tell the FDA to bring it on. Report

> Aurobindo is looking to buy API plants from Actavis. More

> China corruption probe takes a turn into domestic drug distribution business. News

> Ranbaxy manufacturing drama continues with FDA action on API plant. Story

> McKesson recalibrates its EU strategy after Celesio deal nosedives. Article

> Wockhardt hires a new compliance exec in the face of FDA bans. Item

Suggested Articles

Yale scientists have combined the gene-editing system CRISPR with gene therapy to help the immune system find tough-to-spot tumor cells.

The planned deal hit a wall when a special committee set up by Eidos turned down BridgeBio’s third and final offer.

Shares in ReNeuron fell more than one-third after the release of top-line data at the start of the month but the biotech argued the data are positive.